PMID- 12755373
OWN - NLM
STAT- MEDLINE
DCOM- 20031218
LR  - 20191107
IS  - 1023-3830 (Print)
IS  - 1023-3830 (Linking)
VI  - 52
IP  - 3
DP  - 2003 Mar
TI  - Luteolin alleviates bronchoconstriction and airway hyperreactivity in ovalbumin 
      sensitized mice.
PG  - 101-6
AB  - OBJECTIVE AND DESIGN: Asthma is an inflammatory disease of the airways and the 
      current focus in managing asthma is the control of inflammation. In this study, 
      we attempted to investigate the anti-asthmatic potential of a plant derived 
      natural compound, luteolin. MATERIAL: We used a murine model of airway 
      hyperreactivity, which mimicked some of the characteristic features of asthma. 
      Male BALB/c mice (8-9 weeks) were used for this study. TREATMENT: Mice (n = 6) 
      were sensitized by intraperitoneal (i. p.) injection of 10 mg of ovalbumin (OVA) 
      on days 0, 7 and 14 followed by aerosol inhalation (5% OVA) treatments daily 
      beginning from day 19 to day 23. To study its preventive effect, luteolin (0.1, 
      1.0, and 10 mg/kg body weight; daily) was administered orally during the entire 
      period (0 to 23 day) of sensitization. To study its curative effect, mice were 
      first sensitized and then luteolin (1.0 mg/kg body weight daily) was given orally 
      from day 26 to 32. The airway hyperreactivity, immunoglobulin E (IgE) in the 
      sera, and cytokines (IFN-gamma, IL-4 and IL-5) in the bronchoalveolar lavage 
      fluid (BALF) were measured. RESULTS: Both during sensitization and after 
      sensitization, luteolin, at a dose of 0.1 mg/kg body weight, significantly 
      modulated OVA-induced airway bronchoconstriction and bronchial hyperreactivity (p 
      < 0.05). Luteolin also reduced OVA-specific IgE levels in the sera, increased 
      interferon gamma (IFN-gamma) levels and decreased the interleukin-4 (IL-4) and 
      interleukin-5 (IL-5) levels in the BALF. CONCLUSION: Our study showed that 
      luteolin treatment during and after sensitization significantly attenuated the 
      asthmatic features in experimental mice. Therefore, luteolin could be used either 
      as a lead molecule to identify an effective antiasthma therapy or as a means to 
      identify novel anti-asthma targets.
FAU - Das, M
AU  - Das M
AD  - Molecular Immunology and Immunogenetics Lab, Centre for Biochemical Technology, 
      Mall Road, Delhi 110007, India,
FAU - Ram, A
AU  - Ram A
FAU - Ghosh, B
AU  - Ghosh B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Expectorants)
RN  - 0 (Flavonoids)
RN  - 0 (Interleukin-5)
RN  - 0 (Muscarinic Agonists)
RN  - 0W5ETF9M2K (Methacholine Chloride)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9006-59-1 (Ovalbumin)
RN  - KUX1ZNC9J2 (Luteolin)
SB  - IM
MH  - Airway Resistance/physiology
MH  - Animals
MH  - Asthma/drug therapy/physiopathology
MH  - Bronchial Hyperreactivity/*drug therapy/physiopathology
MH  - Bronchoalveolar Lavage Fluid/chemistry
MH  - Bronchoconstriction/*drug effects
MH  - Expectorants/*therapeutic use
MH  - Flavonoids/*therapeutic use
MH  - Immunoglobulin E/metabolism
MH  - Interferon-gamma/metabolism
MH  - Interleukin-4/metabolism
MH  - Interleukin-5/metabolism
MH  - Luteolin
MH  - Male
MH  - Methacholine Chloride/pharmacology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Muscarinic Agonists/pharmacology
MH  - Ovalbumin/*immunology
EDAT- 2003/05/21 05:00
MHDA- 2003/12/19 05:00
CRDT- 2003/05/21 05:00
PHST- 2003/05/21 05:00 [pubmed]
PHST- 2003/12/19 05:00 [medline]
PHST- 2003/05/21 05:00 [entrez]
AID - 10.1007/s000110300021 [doi]
PST - ppublish
SO  - Inflamm Res. 2003 Mar;52(3):101-6. doi: 10.1007/s000110300021.